文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Gut microbiota dynamics and uraemic toxins: one size does not fit all.

作者信息

Joossens Marie, Faust Karoline, Gryp Tessa, Nguyen Anh Thi Loan, Wang Jun, Eloot Sunny, Schepers Eva, Dhondt Annemieke, Pletinck Anneleen, Vieira-Silva Sara, Falony Gwen, Vaneechoutte Mario, Vanholder Raymond, Van Biesen Wim, Huys Geert Roger Bertrand, Raes Jeroen, Glorieux Griet

机构信息

Laboratory of Molecular Bacteriology- Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.

Center for Microbiology, VIB, Leuven, Belgium.

出版信息

Gut. 2019 Dec;68(12):2257-2260. doi: 10.1136/gutjnl-2018-317561. Epub 2018 Nov 21.

DOI:10.1136/gutjnl-2018-317561
PMID:30464044
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6872439/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7428/6872439/ff9ffa005365/gutjnl-2018-317561f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7428/6872439/17337b07844c/gutjnl-2018-317561f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7428/6872439/ff9ffa005365/gutjnl-2018-317561f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7428/6872439/17337b07844c/gutjnl-2018-317561f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7428/6872439/ff9ffa005365/gutjnl-2018-317561f02.jpg

相似文献

[1]
Gut microbiota dynamics and uraemic toxins: one size does not fit all.

Gut. 2019-12

[2]
Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease.

Minerva Endocrinol. 2017-6

[3]
Gut microbiota and non-alcoholic fatty liver disease.

Hepatobiliary Pancreat Dis Int. 2015-12

[4]
The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation.

Hepatol Int. 2015-7

[5]
Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.

Mol Pharm. 2018-8-2

[6]
Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier.

World J Gastroenterol. 2017-1-7

[7]
The role of the gastrointestinal tract and microbiota on uremic toxins and chronic kidney disease development.

Clin Exp Nephrol. 2017-2

[8]
Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice.

Mol Nutr Food Res. 2019-2-4

[9]
[Gut microbiota and kidney diseases : dangerous liaisons?].

Rev Med Suisse. 2018-2-21

[10]
Emodin via colonic irrigation modulates gut microbiota and reduces uremic toxins in rats with chronic kidney disease.

Oncotarget. 2016-4-5

引用本文的文献

[1]
A specifically designed multi-biotic reduces uremic toxin generation and improves kidney function.

Gut Microbes. 2025-12

[2]
Pediatric and adult point of view on the gut-kidney axis in CKD.

Pediatr Nephrol. 2025-7-7

[3]
A bibliometric study of global trends in diabetic nephropathy and intestinal flora research.

Front Microbiol. 2025-5-21

[4]
Regulation of the blood-brain barrier function by peripheral cues in health and disease.

Metab Brain Dis. 2024-12-13

[5]
Future of Uremic Toxin Management.

Toxins (Basel). 2024-10-28

[6]
The effect of synbiotic supplementation on plasma levels of advanced glycation end products and cardiovascular risk factors in hemodialysis patients: A double-blind clinical trial.

Food Sci Nutr. 2024-7-12

[7]
Clinical Perspectives of Gut Microbiota in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: Where Do We Stand?

Biomedicines. 2023-9-7

[8]
Underdevelopment of gut microbiota in failure to thrive infants of up to 12 months of age.

Front Cell Infect Microbiol. 2022

[9]
A novel therapeutic concern: Antibiotic resistance genes in common chronic diseases.

Front Microbiol. 2022-10-17

[10]
Enterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota.

Acta Biochim Biophys Sin (Shanghai). 2022-10-25

本文引用的文献

[1]
Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.

Gut. 2018-8-31

[2]
Gut-Derived Metabolites and Chronic Kidney Disease: The Forest (F)or the Trees?

Clin J Am Soc Nephrol. 2018-9-7

[3]
Spontaneous variability of pre-dialysis concentrations of uremic toxins over time in stable hemodialysis patients.

PLoS One. 2017-10-10

[4]
Population-level analysis of gut microbiome variation.

Science. 2016-4-28

[5]
Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial.

Clin J Am Soc Nephrol. 2016-2-5

[6]
The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease.

Kidney Int. 2013-1-16

[7]
Chronic kidney disease alters intestinal microbial flora.

Kidney Int. 2012-9-19

[8]
Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients.

Clin J Am Soc Nephrol. 2009-8-20

[9]
p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin.

Nephrol Dial Transplant. 2009-8-19

[10]
Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis.

Nephron. 1996

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索